Loading

Please wait...

Hemlibra

Generic Name: emicizumab (EM a SIZ ue mab)
Brand Names: Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that is missing in people with hemophilia A. It works as a
  • Prescription Settings

Prices and coupons of Hemlibra

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Hemlibra (emicizumab) is a monoclonal antibody that functions in place of a natural blood-clotting factor that is missing in people with hemophilia A. Emicizumab works as a "bridge" between other clotting factors to replace missing factor VIII. Hemlibra is for adults and children with hemophilia A with or without factor VIII inhibitors. Hemlibra is used to help prevent bleeding episodes or make them occur less often. Hemlibra will not stop a bleeding episode that has already begun. Hemlibra can cause unwanted blood clots when used together with a bypassing agent such as FEIBA. This can damage small blood vessels in your arms and legs, brain, kidneys, lungs, or other organs. Learn more

Hemlibra Side Effects

Hemlibra Side Effects

Note: This document contains side effect information about emicizumab. Some of the dosage forms listed on this page may not apply to the brand name Hemlibra.

For the Consumer

Applies to emicizumab: subcutaneous solution

Warning

Subcutaneous route (Solution)

Warning: Thrombotic Microangiopathy and ThromboembolismCases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of greater than 100 units/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving emicizumab-kxwh prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of emicizumab-kxwh if symptoms occur.

Along with its needed effects, emicizumab (the active ingredient contained in Hemlibra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking emicizumab:

Incidence not known

  • Blue-green to black skin discoloration
  • changes in skin color, pain, tenderness, or swelling of the foot or leg
  • pain, redness, or sloughing of the skin at the injection site
  • sudden weakness in the arms or legs
  • sudden, severe chest pain

Some side effects of emicizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • headache
  • diarrhea
  • difficulty in moving
  • fever
  • joint pain or swelling
  • muscle aches, cramps, pain, or stiffness
  • muscle pain or stiffness

For Healthcare Professionals

Applies to emicizumab: subcutaneous solution

General

The most common adverse reactions were injection site reactions, antibody formation, headache, injection site erythema, and arthralgia.

Cardiovascular

Common (1% to 10%): Thrombotic microangiopathy, thrombotic events

Frequency not reported: Superficial thrombophlebitis

Local

Very common (10% or more): Injection site reactions (22%), injection site erythema (11%)

Common (1% to 10%): Injection site pain, injection site pruritus

Nervous system

Very common (10% or more): Headache (15%)

Musculoskeletal

Very common (10% or more): Arthralgia (10%)

Common (1% to 10%): Myalgia

Uncommon (0.1% to 1%): Rhabdomyolysis, serum creatine kinase elevated

Gastrointestinal

Common (1% to 10%): Diarrhea

Immunologic

Very common (10% or more): Antibody formation (up to 22%)

Other

Common (1% to 10%): Pyrexia

Dermatologic

Frequency not reported: Skin necrosis

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Hemlibra